John Vavricka's most recent trade in Atea Pharmaceuticals Inc was a trade of 119,520 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 119,520 | 119,520 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 42,083 | 94,164 | - | - | Common Stock | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 33,333 | 0 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.24 per share. | 31 Jan 2026 | 11,570 | 82,594 | - | 4.2 | 49,057 | Common Stock |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 8,750 | 0 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 132,800 | 132,800 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 54,848 | - | - | Common Stock | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 33,333 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 11,517 | 52,081 | - | 3.1 | 35,242 | Common Stock |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,750 | 63,598 | - | - | Common Stock | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,750 | 8,750 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Vavricka John | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 132,800 | 132,800 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | Vavricka John | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 66,666 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Vavricka John | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 33,334 | - | - | Common Stock | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 11,819 | 21,515 | - | 3.8 | 45,420 | Common Stock |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | John Vavricka | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) |